Mixed Lineage Kinase

Mixed Lineage Kinase阻害剤の選択性比較

Mixed Lineage Kinase製品

  • All (5)
  • Mixed Lineage Kinase阻害剤 (4)
  • Mixed Lineage Kinase活性剤(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Cancer Cell, 2022, S1535-6108(22)00312-9
Cell Rep, 2022, 38(8):110414
Mol Cell, 2021, S1097-2765(21)00264-1
S2805 LY364947 LY364947 (HTS 466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II.
Cell Rep, 2022, 38(5):110329
Front Immunol, 2022, 13:853894
Aging Dis, 2022, 13(1):313-328
S7343 URMC-099 URMC-099 is an orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor with IC50 of 19 nM, 42 nM, 14 nM, and 150 nM, for MLK1, MLK2, MLK3, and DLK, respectively, and also inhibits LRRK2 activity with IC50 of 11 nM. URMC-099 also inhibits ABL1 with IC50 of 6.8 nM. URMC-099 induces autophagy.
Cell Rep, 2021, 35(1):108940
JCI Insight, 2021, 149075
Cancer Cell Int, 2021, 21(1):24
S8251 Necrosulfonamide Necrosulfonamide is a very specific and potent necrosis inhibitor and blocks mixed lineage kinase domain-like protein (MLKL).
Cell Metab, 2022, S1550-4131(22)00054-7
Sci Immunol, 2022, 7(68):eabk2092
Nat Commun, 2022, 13(1):494
S3238 Resibufogenin Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. Resibufogenin exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. Resibufogenin induces apoptosis and caspase-3 and caspase-8 activity. Resibufogenin increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
Phytomedicine, 2022, 102:154182
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Cancer Cell, 2022, S1535-6108(22)00312-9
Cell Rep, 2022, 38(8):110414
Mol Cell, 2021, S1097-2765(21)00264-1
S2805 LY364947 LY364947 (HTS 466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II.
Cell Rep, 2022, 38(5):110329
Front Immunol, 2022, 13:853894
Aging Dis, 2022, 13(1):313-328
S7343 URMC-099 URMC-099 is an orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor with IC50 of 19 nM, 42 nM, 14 nM, and 150 nM, for MLK1, MLK2, MLK3, and DLK, respectively, and also inhibits LRRK2 activity with IC50 of 11 nM. URMC-099 also inhibits ABL1 with IC50 of 6.8 nM. URMC-099 induces autophagy.
Cell Rep, 2021, 35(1):108940
JCI Insight, 2021, 149075
Cancer Cell Int, 2021, 21(1):24
S8251 Necrosulfonamide Necrosulfonamide is a very specific and potent necrosis inhibitor and blocks mixed lineage kinase domain-like protein (MLKL).
Cell Metab, 2022, S1550-4131(22)00054-7
Sci Immunol, 2022, 7(68):eabk2092
Nat Commun, 2022, 13(1):494
S3238 Resibufogenin Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. Resibufogenin exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. Resibufogenin induces apoptosis and caspase-3 and caspase-8 activity. Resibufogenin increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
Phytomedicine, 2022, 102:154182
Tags: MLK Inhibitors | MLKL Review